Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials ofÂ Patients With Nonalcoholic Steatohepatitis

Article ID	Journal	Published Year	Pages	File Type
3282595	Clinical Gastroenterology and Hepatology	2014	12 Pages	PDF

Abstract

Despite a relevant mechanism of action, ASP9831 did not significantly alter the biochemical markers of NASH, compared with placebo, in a clinical trial. This highlights the difficulties of developing therapeutics for NASH and the need for more extensive preclinical testing of mechanisms of potential drug candidates. Clinicaltrialsregister.eu: 2005-001687-31; EudraCT numbers: 2007-002114-19.

Keywords

Cmax TNF PDE4 methionine-choline deficient MCD tmax ALT PDE LPS AUC cAMP TEAE adenosine 3′,5′-cyclic monophosphate AST Aspartate aminotransferase Alanine aminotransferase nonalcoholic steatohepatitis Therapeutic targets Fatty liver disease maximum drug concentration Treatment adverse event treatment-emergent adverse event tumor necrosis factor Phosphodiesterase lipopolysaccharide Nash

Related Topics

Health Sciences Medicine and Dentistry Gastroenterology

Preview

Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials ofÂ Patients With Nonalcoholic Steatohepatitis

Authors

Vlad Ratziu, Pierre Bedossa, Sven M. Francque, Dominique Larrey, Guruprasad P. Aithal, Lawrence Serfaty, Mihai Voiculescu, Liliana Preotescu, Frederik Nevens, Victor De Lédinghen, Gabriele I. Kirchner, Pavel Trunecka, Stephen D. Ryder,